Raymond James & Associates Cyclerion Therapeutics, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 04, 2020
SELL
$3.46 - $8.39 $74,663 - $181,047
-21,579 Closed
0 $0
Q2 2020

Jul 28, 2020
BUY
$2.37 - $7.14 $51,142 - $154,074
21,579 New
21,579 $128,000

Others Institutions Holding CYCN

# of Institutions
1
Shares Held
293K
Call Options Held
0
Put Options Held
0
View Full List

About Cyclerion Therapeutics, Inc.

CYCN Quotes by TradingView
  • Ticker CYCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,479,800
  • Market Cap $148M
  • Description
  • Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...
More about CYCN
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email